Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
This article was originally published in PharmAsia News
Executive Summary
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.
You may also be interested in...
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports